Bone metastases: molecular mechanisms and novel therapeutic interventions (Q37785505)

23 August 2017

Bone metastases: molecular mechanisms and novel therapeutic interventions (English)

1 reference

23 August 2017

2

Efthimia K Basdra

1 reference

23 August 2017

Dionysios J Papachristou

series ordinal

1

1 reference

PubMed ID

20818675

23 August 2017

Athanasios G Papavassiliou

series ordinal

3

1 reference

23 August 2017

3 September 2010

1 reference

Medicinal Research Reviews

23 August 2017

1 reference

23 August 2017

32

1 reference

23 August 2017

3

1 reference

23 August 2017

611-636

1 reference

The clinical course of bone metastases from breast cancer

23 August 2017

1 reference

THE FUNCTION OF THE VERTEBRAL VEINS AND THEIR ROLE IN THE SPREAD OF METASTASES

21 January 2018

1 reference

Bone remodeling: Multiple cellular interactions required for coupling of bone formation and resorption

21 January 2018

1 reference

Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus

21 January 2018

1 reference

Osteoclast differentiation and activation

21 January 2018

1 reference

Functions of RANKL/RANK/OPG in bone modeling and remodeling

21 January 2018

1 reference

Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone.

21 January 2018

1 reference

The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion

21 January 2018

1 reference

Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone

21 January 2018

1 reference

Molecular and cellular mechanisms of the anabolic effect of intermittent PTH

21 January 2018

1 reference

T cells potentiate PTH-induced cortical bone loss through CD40L signaling

21 January 2018

1 reference

Osteoclast-derived activity in the coupling of bone formation to resorption.

21 January 2018

1 reference

A physical mechanism for coupling bone resorption and formation in adult human bone.

21 January 2018

1 reference

Metastasis to bone: causes, consequences and therapeutic opportunities

21 January 2018

1 reference

Mechanisms of bone metastasis

21 January 2018

1 reference

Parathyroid hormone-related protein localization in breast cancers predict improved prognosis.

21 January 2018

1 reference

TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development

21 January 2018

1 reference

Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells

21 January 2018

1 reference

IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae

21 January 2018

1 reference

Osteotropic cancers: from primary tumor to bone

21 January 2018

1 reference

Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone

21 January 2018

1 reference

Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases

21 January 2018

1 reference

Regulation of cancer cell migration and bone metastasis by RANKL.

21 January 2018

1 reference

Chemokines: a new classification system and their role in immunity

21 January 2018

1 reference

The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis

21 January 2018

1 reference

Involvement of chemokine receptors in breast cancer metastasis

21 January 2018

1 reference

Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4.

21 January 2018

1 reference

Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo.

21 January 2018

1 reference

CXCR4 regulates growth of both primary and metastatic breast cancer

21 January 2018

1 reference

A multigenic program mediating breast cancer metastasis to bone

21 January 2018

1 reference

Endothelial cells and normal breast epithelial cells enhance invasion of breast carcinoma cells by CXCR-4-dependent up-regulation of urokinase-type plasminogen activator receptor (uPAR, CD87) expression.

21 January 2018

1 reference

Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression.

21 January 2018

1 reference

Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis

21 January 2018

1 reference

Hypoxia--a key regulatory factor in tumour growth

21 January 2018

1 reference

Transcription. Oxygen sensing gets a second wind

21 January 2018

1 reference

Role of HIF-1alpha in skeletal development.

21 January 2018

1 reference

Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer.

21 January 2018

1 reference

Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment

21 January 2018

1 reference

Leptin regulation of bone resorption by the sympathetic nervous system and CART

21 January 2018

1 reference

Regulation of bone remodeling by the central and peripheral nervous system

21 January 2018

1 reference

Leptin regulates bone formation via the sympathetic nervous system

21 January 2018

1 reference

The molecular clock mediates leptin-regulated bone formation.

21 January 2018

1 reference

Use of markers of bone turnover for monitoring bone metastases and the response to therapy

21 January 2018

1 reference

The endothelin axis in cancer

21 January 2018

1 reference

Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors

21 January 2018

1 reference

Growth regulatory properties of endothelins

21 January 2018

1 reference

Upregulation of endothelin 1 and its precursor by IL-1beta, TNF-alpha, and TGF-beta in the PC3 human prostate cancer cell line

21 January 2018

1 reference

Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption

21 January 2018

1 reference

A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases

21 January 2018

1 reference

Role of endothelin-1 in osteoblastic bone metastases

21 January 2018

1 reference

Evolving role of uPA/uPAR system in human cancers

21 January 2018

1 reference

The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy.

21 January 2018

1 reference

Prostate cancer bone metastases promote both osteolytic and osteoblastic activity

21 January 2018

1 reference

Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.

21 January 2018

1 reference

RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo

21 January 2018

1 reference

Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover.

21 January 2018

1 reference

Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease

21 January 2018

1 reference

Wnt/beta-catenin signaling in development and disease

21 January 2018

1 reference

An arrow for wingless to take-off

21 January 2018

1 reference

The Wnt signaling pathway and bone metabolism

21 January 2018

1 reference

Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation

21 January 2018

1 reference

Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation

21 January 2018

1 reference

Role of Wnts in prostate cancer bone metastases

21 January 2018

1 reference

Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications.

21 January 2018

1 reference

Prospective identification of tumorigenic breast cancer cells

21 January 2018

1 reference

ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome

21 January 2018

1 reference

The prognostic role of a gene signature from tumorigenic breast-cancer cells.

21 January 2018

1 reference

CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis

21 January 2018

1 reference

Cancer stem cells in breast cancer and metastasis

21 January 2018

1 reference

WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics

21 January 2018

1 reference

Tumor dormancy: death and resurrection of cancer as seen through transgenic mouse models

21 January 2018

1 reference

Uncertainty in the niches that maintain haematopoietic stem cells

21 January 2018

1 reference

Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells

21 January 2018

1 reference

Gene expression profiling predicts clinical outcome of breast cancer

21 January 2018

1 reference

Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors

21 January 2018

1 reference

Breast cancer metastasis: markers and models

21 January 2018

1 reference

MicroRNAs: Crucial multi-tasking components in the complex circuitry of tumor metastasis

21 January 2018

1 reference

microRNA, cell cycle, and human breast cancer

21 January 2018

1 reference

Molecular mechanisms of action of bisphosphonates: current status.

21 January 2018

1 reference

Bisphosphonates: clinical experience

21 January 2018

1 reference

Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro.

21 January 2018

1 reference

Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure

21 January 2018

1 reference

Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients

21 January 2018

1 reference

Pulse treatment with zoledronic acid causes sustained commitment of bone marrow derived mesenchymal stem cells for osteogenic differentiation.

21 January 2018

1 reference

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases

21 January 2018

1 reference

Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.

21 January 2018

1 reference

Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.

21 January 2018

1 reference

Osteonecrosis of the jaw: who gets it, and why?

21 January 2018

1 reference

A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer

21 January 2018

1 reference

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer

21 January 2018

1 reference

Bone density, strength, and formation in adult cathepsin K (-/-) mice

21 January 2018

1 reference

Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency

21 January 2018

1 reference

Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies.

21 January 2018

1 reference

Future therapeutic targets in osteoporosis

21 January 2018

1 reference

21 January 2018

A renaissance for SRC

1 reference

The role of Src in solid tumors

21 January 2018

1 reference

The interplay between Src family kinases and receptor tyrosine kinases

21 January 2018

1 reference

c-Src and cooperating partners in human cancer

21 January 2018

1 reference

Targeting Src in breast cancer

21 January 2018

1 reference

Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity

21 January 2018

1 reference

Increased levels of active c-Src distinguish invasive from in situ lobular lesions

21 January 2018

1 reference

Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice

21 January 2018

1 reference

Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src-/- mutant mice

21 January 2018

1 reference

Latent bone metastasis in breast cancer tied to Src-dependent survival signals

21 January 2018

1 reference

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro

21 January 2018

1 reference

Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy

21 January 2018

1 reference

Targeting bone metastasis in prostate cancer with endothelin receptor antagonists

21 January 2018

1 reference

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.

21 January 2018

1 reference

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer

21 January 2018

1 reference

Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis

21 January 2018

1 reference

Skeletal metastasis: Established and emerging roles of parathyroid hormone related protein (PTHrP).

21 January 2018

1 reference

Emerging therapeutic targets in breast cancer bone metastasis

21 January 2018

1 reference

A soluble activin type IIA receptor induces bone formation and improves skeletal integrity

21 January 2018

1 reference

Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling

21 January 2018

1 reference

Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis

21 January 2018

1 reference

Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases.

21 January 2018

1 reference

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/MED.20224

1 reference

23 August 2017

1 reference

PubMed ID

20818675